Summary
Vertex Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing transformative medicines, with a primary emphasis on cystic fibrosis (CF). The company's two key marketed products are KALYDECO and ORKAMBI, both targeting specific mutations in the CFTR gene. ORKAMBI, approved in mid-2015, saw significant revenue generation starting in the latter half of the year, with plans for label expansion to younger patients. KALYDECO continued to contribute substantially to revenue, with expectations of further growth through label expansions. Vertex is actively advancing its pipeline with multiple CF drug candidates, including VX-661 in combination with ivacaftor and next-generation correctors like VX-152 and VX-440, aiming for improved treatment regimens. Beyond CF, the company is also exploring opportunities in oncology, pain, and neurology, with several candidates in early-stage clinical development. Despite substantial investment in research and development, Vertex reported net losses for the period, a common characteristic for companies in this stage of drug development. Significant upcoming milestones include potential regulatory submissions for expanded ORKAMBI indications and continued clinical trial progress for its pipeline assets.
Financial Highlights
51 data points| Revenue | $1.03B |
| Cost of Revenue | $117.15M |
| Gross Profit | $915.18M |
| R&D Expenses | $995.92M |
| SG&A Expenses | $376.57M |
| Operating Expenses | $1.50B |
| Operating Income | -$466.88M |
| Net Income | -$556.33M |
| EPS (Basic) | $-2.31 |
| EPS (Diluted) | $-2.31 |
| Shares Outstanding (Basic) | 241.31M |
| Shares Outstanding (Diluted) | 241.31M |
Key Highlights
- 1Vertex Pharmaceuticals reported significant revenue growth in 2015, primarily driven by the launch of ORKAMBI, approved in July 2015, and continued strong performance from KALYDECO.
- 2ORKAMBI generated $350.7 million in net product revenues in 2015, with over 4,500 patients in the U.S. starting treatment by year-end, and plans for label expansion to younger CF patients (6-11 years old).
- 3KALYDECO's net product revenues increased to $631.7 million in 2015, benefiting from label expansions and ongoing reimbursement efforts in ex-U.S. markets.
- 4The company has a robust pipeline with multiple CF drug candidates in Phase 3 development, including VX-661 in combination with ivacaftor, and early-stage programs in oncology (VX-970), pain (VX-150), and spinal cord injury (VX-210).
- 5Vertex made significant strategic investments in 2015, including a collaboration with CRISPR Therapeutics for gene editing, and with Parion Sciences for ENaC inhibitors, signaling a commitment to expanding its therapeutic reach.
- 6Despite revenue growth, Vertex reported a net loss of $556.3 million for 2015, reflecting substantial ongoing investments in research and development.
- 7The company's financial position remained strong, with $1.04 billion in cash, cash equivalents, and marketable securities as of December 31, 2015, providing resources to fund ongoing operations and development.